Valneva SE | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
40,167.00
29,468.00
42,567.00
42,180.00
38,055.00
81,725
Total Accounts Receivable
7,570.00
6,850.00
15,754.00
16,912.00
17,622.00
11,259
Inventories
4,819.00
7,282.00
26,687.00
22,701.00
19,931.00
22,727
Other Current Assets
10,790.00
9,367.00
31,375.00
9,404.00
7,840.00
10,261
Total Current Assets
63,346.00
52,967.00
116,383.00
91,197.00
83,448.00
125,972
Net Property, Plant & Equipment
45,067.00
41,611.00
42,439.00
39,039.00
38,374.00
37,997
Intangible Assets
125,403.00
105,204.00
98,567.00
58,959.00
48,468.00
44,891
Other Assets
20,575.00
27,735.00
17,798.00
17,688.00
17,367.00
17,059
Total Assets
254,391.00
227,517.00
275,187.00
206,883.00
189,343.00
239,829
ST Debt & Current Portion LT Debt
6,381.00
7,117.00
25,687.00
20,959.00
17,399.00
Accounts Payable
6,487.00
5,192.00
6,325.00
2,554.00
5,258.00
Income Tax Payable
-
-
425.00
561.00
322.00
Other Current Liabilities
15,232.00
14,078.00
13,926.00
14,817.00
14,695.00
Total Current Liabilities
28,100.00
26,387.00
46,363.00
38,891.00
37,674.00
Long-Term Debt
64,902.00
66,036.00
76,568.00
61,544.00
54,097.00
Provision for Risks & Charges
-
-
-
-
295.00
Deferred Taxes
-
-
111.00
65.00
1,621.00
Other Liabilities
17,278.00
10,650.00
7,810.00
6,332.00
4,543.00
Total Liabilities
110,280.00
103,073.00
130,852.00
106,832.00
96,674.00
Common Equity (Total)
144,111.00
124,444.00
144,335.00
100,051.00
92,669.00
Total Shareholders' Equity
144,111.00
124,444.00
144,335.00
100,051.00
92,669.00
Total Equity
144,111.00
124,444.00
144,335.00
100,051.00
92,669.00
Liabilities & Shareholders' Equity
254,391.00
227,517.00
275,187.00
206,883.00
189,343.00

About Valneva SE

View Profile
Address
Campus Bio-Ouest 6
Saint-Herblain Lorraine 44800
France
Employees -
Website http://www.valneva.com
Updated 07/08/2019
Valneva SE is a biotech company which engages in the development, production, and marketing of vaccine and preventive medicine. It operates through the following segments: Commercialized Vaccines, Technologies and Services, and Vaccine Candidates. The Commercialized Vaccines segment includes currently marketed vaccines of the group such as JEV and DUKORAL.